Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Galapagos   /   Galapagos juli 2017

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,500   0,000   (0,00%) Dagrange 25,140 - 25,720 57.513   Gem. (3M) 87,9K

Galapagos juli 2017

Volgen
2.236 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 112 »» | Laatste | Omlaag ↓
  11. me_n 3 juli 2017 15:00
    quote:

    _Giulietta_ schreef op 3 juli 2017 14:41:

    [...]

    Vandaag gewoon nog online geweest, maar wat valt er te zeggen? Het is voor nu gewoon even afwachten tot verdere ontwikkelingen.
    Valt best wat te zeggen na de R&D update denk ik. Analisten hadden ook wel wat te zeggen daarna, zijn genoeg koersdoel verlagingen geweest...
    Ja wachten en vasthouden die aandelen. (al is het soms moeilijk)
  16. durobinet 3 juli 2017 15:13
    Van zowel Lynx als IB ontvangen:
    We would like to inform you that one or more companies in which you hold positions will announce earnings soon with consensus estimates as detailed below. Please see KB2133 to learn more about trading strategies some investors use in connection with earnings announcements.

    Underlying Quarter
    Consensus EPS
    Consensus Revenue
    Currency
    Date When Announced
    Avg 1-Week
    Move*
    Accounts
    GLPG Q2 '17
    -0.59
    N/A
    EUR 2017-07-27 IntraDay
    N/A U****266
    *Represents the average change in stock price over the one-week period following the past four earnings announcements.
  17. egeltjemetstekel 3 juli 2017 15:27
    Was dit al geplaatst? Geen idee....:

    www.themarketsdaily.com/2017/07/01/ga...

    Galapagos NV (GLPG) Earning Positive Press Coverage, Analysis Shows
    Posted by Danessa Lincoln on Jul 1st, 2017 // No Comments
    Galapagos NV logoMedia coverage about Galapagos NV (NASDAQ:GLPG) has trended positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galapagos NV earned a daily sentiment score of 0.37 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
    These are some of the news stories that may have effected Accern Sentiment’s analysis:
    Get Galapagos NV alerts:
    Brokerages Set Galapagos NV (NASDAQ:GLPG) PT at $102.50 – The Momentous News (momentousnews.com)
    Belgium stocks lower at close of trade; BEL 20 down 0.08% By … – Investing.com (investing.com)
    Galapagos NV (GLPG) Short Interest Up 39.5% in June (americanbankingnews.com)
    Near-Term, Can These Stocks Move the Needle: Galapagos NV (NASDAQ:GLPG) and Sensient Technologies … – FLBC News (flbcnews.com)
    Galapagos NV (GLPG) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
    A number of equities analysts recently commented on GLPG shares. Stifel Nicolaus upped their price target on shares of Galapagos NV from $65.00 to $83.00 and gave the company a “hold” rating in a report on Monday, May 1st. Janney Montgomery Scott lowered shares of Galapagos NV from a “buy” rating to a “sell” rating in a research note on Monday, April 24th. TheStreet raised shares of Galapagos NV from a “d+” rating to a “c” rating in a research note on Wednesday, May 17th. Zacks Investment Research downgraded shares of Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday, April 24th. Finally, BTIG Research reiterated a “buy” rating and set a $98.00 price target on shares of Galapagos NV in a research note on Tuesday, June 20th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. Galapagos NV currently has a consensus rating of “Buy” and an average target price of $94.00.


    Galapagos NV (NASDAQ GLPG) traded up 0.35% on Friday, reaching $76.52. 178,233 shares of the company’s stock were exchanged. Galapagos NV has a 12 month low of $51.91 and a 12 month high of $94.88.
    Galapagos NV Company Profile
    Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

2.236 Posts
Pagina: «« 1 ... 3 4 5 6 7 ... 112 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Galapagos meldt fraai succes rond nieuwe therapie: zit er weer muziek in het aandeel?

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. Galapagos: bemoedigende nieuwe resultaten met recidief/refractair non-Hodgkin lymfoom
  2. Kepler Cheuvreux zet Galapagos op verkooplijst
  3. Klinische resultaten Galapagos steunen celtherapie-hypothese
  4. Deutsche Bank verlaagt koersdoel Galapagos
  5. Financials en Shell doen goede zaken op terughoudend Damrak
  6. Galapagos herhaalt cash burn voor 2024
  7. Galapagos benoemt investeerder Nodelman in bestuur
  8. EcoR1 nog groter in Galapagos
  9. EcoR1 groter in Galapagos
  10. FMR LLC kleiner in Galapagos